Document is current
Any future updates will be listed below
-
Authors
Belbellaj, Wiame
Lona-Durazo, Frida
Bodano, Cinzia
Busseuil, David
Cyr, Marie-Christyne
Fiorillo, Edoardo
Mulas, Antonella
Provost, Sylvie
Steri, Maristella
Tanaka, Toshiko
Vanderwerff, Brett
Wang, Jiongming
Byrne, Ross P.
Cucca, Francesco
Dubé, Marie-Pierre
Ferrucci, Luigi
McLaughlin, Russell L.
Tardif, Jean-Claude
Zawistowski, Matthew
Gagliano Taliun, Sarah A.
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé,Canada
Motor Neurone Disease Association
Canada Research Chairs,Canada
Alzheimer Society,Canada
Canadian Institutes of Health Research,Canada
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 11 October 2024
First Online: 19 October 2024
Declarations
:
: MPD has minor equity interest in Dalcor Pharmaceuticals. MPD has a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute. JCT holds research grants from Amarin, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Merck, Novartis and Pfizer; fees from DalCor Pharmacuticals, HLS Pharmaceuticals, Pendopharm and Pfizer; and minor equity interest from DalCor Pharmaceuticals. The other authors declare no competing interests.
